SpyGlass Pharma Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission file number 001-43105___________________________ SpyGlass Pharma, Inc. (Exact name of registrant as specified in its charter)___________________________ (State or other jurisdiction ofincorporation or organization) (949) 284-6904(Registrant’s telephone number, including area code) 27061 Aliso Creek Rd., Suite 100Aliso Viejo, California 92656(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growthcompany" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo Table of Contents PART IFINANCIAL INFORMATION5Item 1Financial Statements (Unaudited)5Condensed Balance Sheets5Condensed Statements of Operations and Comprehensive Loss6Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders’Equity(Deficit)7Condensed Statements of Cash Flows9Notes to Condensed Financial Statements10Item 2Management's Discussion and Analysis of Financial Condition and Results of Operations20Item 3Quantitative and Qualitative Disclosures About Market Risk28Item 4Controls and Procedures28 PART IIOTHER INFORMATION Item 1Legal Proceedings29Item 1ARisk Factors29Item 2Unregistered Sales of Equity Securities and Use of Proceeds89Item 3Defaults Upon Senior Securities89Item 4Mine Safety Disclosures89Item 5Other Information89Item 6Exhibits90Signatures91 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Actof 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the ExchangeAct), that are based on our management’s beliefs and assumptions and on information currently available to our management.All statements other than statements of historical fact contained in this Quarterly Report, including statements regarding ourplans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relatingto product candidates and markets and business trends are forward-looking statements. In some cases, you can identifyforward-looking statements because they contain words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, “aim” or “continue” or the negative of thesewords or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results,performance or achievements to be materially different from any future results, performance or achievements expressed orimplied by the forward-looking statements. Forward-looking statements contained in this Quarterly Report include, but are notlimited to, statements about: the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results;the timing, progress and results of our ongoing and planned clinical trials for our current product candidates, includingstatements regarding enrollment, the timing of completion of trials, and the reporting of data from our current trials, aswell as the timing, progress and results of our current and future preclinical studies;our plans relating to